MODERATOR(S)
Shalini Moningi, MD - Cleveland Clinic Taussig Cancer Institute
session DESCRIPTION
The incidence of three major genitourinary cancers including prostate cancer, bladder cancer and renal cell carcinoma, has substantially increased. Alongside surgical interventions, systemic therapies like chemotherapy, radiotherapy and hormone therapy are utilized in treating genitourinary cancers. Nevertheless, these approaches face limitations stemming from tumor heterogeneity, clinical variability and drug resistance, often yielding unsatisfactory outcomes. Biomarkers play a pivotal role in early tumor diagnosis, drug development, disease monitoring and prognosis evaluation. Therefore, investigating potential urogenital tumor biomarkers will aid in identifying therapeutic targets, enhancing the efficacy of immune and targeted therapies, and bolstering comprehensive patient management for urogenital tumors. Over the past five years, there have been large changes and advances in biomarkers for bladder, renal and prostate cancer. There has been an increased usage of biomarkers, for example, Decipher, Artera, ctDNA, VALOR labs etc. in prostate, bladder and renal cancers. Additionally, there is increased data supporting the role of biomarkers in treatment selection, de-escalation and/or intensification of treatment in multiple GU disease sites. The goal of this session will be to review the latest data in each disease site as well as provide some real-world patient examples and how to use biomarkers to help with treatment decision making.
learning objectives
- Give learners the opportunity to increase their knowledge on the current available biomarkers in the GU space in bladder, renal and prostate cancer and appropriate clinical scenarios to use these biomarkers.
- Give learners the opportunity to increase their knowledge on data supporting the use of biomarkers in the treatment decision making for bladder, renal and prostate cancer.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
03:45pm - 03:47pm ETSpeaker: Shalini Moningi, MD - Cleveland Clinic Taussig Cancer Institute, Cleveland
-
03:47pm - 04:02pm ETSpeaker: Kent Mouw, MD, PhD - Dana-Farber Cancer Institute, Boston
-
04:02pm - 04:17pm ETSpeaker: Shalini Moningi, MD - Cleveland Clinic Taussig Cancer Institute, Cleveland
-
04:17pm - 04:32pm ETSpeaker: Daniel Spratt, MD - University Hospitals Seidman Cancer Center, Case Western Reserve University, Beachwood
-
04:32pm - 04:47pm ETSpeaker: Chad Tang, MD - MD Anderson Cancer Center, Houston
-
04:47pm - 05:00pm ETSpeaker: Shalini Moningi, MD - Cleveland Clinic Taussig Cancer Institute, Cleveland